
DoxyPEP Roll-Out Reduces STI Rates in Major US City
San Francisco's implementation of DoxyPEP, a single-dose antibiotic for STI prevention, has led to a 58% decrease in STIs among gay men and trans women. The CDC has approved the treatment, and real-world results align with trial data, showing promising outcomes in reducing STI rates. However, its effectiveness in reducing gonorrhea and chlamydia levels needs further research. The new tool is seen as an exciting addition to existing STI prevention strategies.


